Wang G, Song M, Xu H, Fang Y
Department of Radiotherapy, East China Hospital, Shanghai, China.
Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):309-13. doi: 10.1016/0360-3016(95)02111-6.
This article is a prospective trial of hyperfractional radiotherapy with bronchial arterial infusion of anticancer drugs to treat locally advanced bronchogenic cancer. The treatment results, the complications of bronchial arterial infusion, the failure patterns, the relationship of technical aspects of delivery of radiotherapy, and the protocol of anticancer drugs are presented.
One hundred and twenty-six patients with locally advanced bronchogenic cancer, treated from January 1988 to January 1990, were divided randomly into four groups in our hospital. Group 1: combination of hyperfractional radiotherapy with bronchial arterial infusion of anticancer drugs (30 cases); Group 2: combination of conventional radiotherapy with bronchial arterial infusion of anticancer (33 cases); Group 3: combination of systemic chemotherapy and split-course radiotherapy (33 cases); Group 4: conventional radiotherapy only (30 cases).
All the patients were followed for 3 years. The 1-year survival rates for Groups 1, 2, 3, and 4 are 80, 63.6, 48.5, and 30%, respectively. The 2-year survival rates for Groups 1, 2, 3, and 4 are 23.3, 15.15, 9.1, and 6.6%, respectively. The 3-year survival rates for Groups 1, 2, 3, and 4 are 10, 3.3, 0, and 0%, respectively.
This study demonstrated that the combination of hyperfractional radiotherapy with bronchial arterial infusion anticancer drugs can be performed safely and effectively for locally advanced bronchogenic carcinoma.
本文是一项关于超分割放疗联合支气管动脉灌注抗癌药物治疗局部晚期支气管源性癌的前瞻性试验。文中呈现了治疗结果、支气管动脉灌注的并发症、失败模式、放疗技术方面的关系以及抗癌药物方案。
1988年1月至1990年1月期间在我院接受治疗的126例局部晚期支气管源性癌患者被随机分为四组。第1组：超分割放疗联合支气管动脉灌注抗癌药物（30例）；第2组：常规放疗联合支气管动脉灌注抗癌药物（33例）；第3组：全身化疗联合分段放疗（33例）；第4组：仅行常规放疗（30例）。
所有患者均随访3年。第1、2、3、4组的1年生存率分别为80%、63.6%、48.5%和30%。第1、2、3、4组的2年生存率分别为23.3%、15.15%、9.1%和6.6%。第1、2、3、4组的3年生存率分别为10%、3.3%、0%和0%。
本研究表明，超分割放疗联合支气管动脉灌注抗癌药物可安全有效地用于治疗局部晚期支气管源性癌。
